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Background
Family history has long been recognized to be a potent risk
factor for breast cancer [1]. Family histories often comprise
only one or two affected relatives, who frequently were not
particularly young at onset. Occasionally, a family contains a
striking constellation of young-onset breast (and often other)
cancers apparently transmitted as a dominant genetic trait.
Over a century ago, the much referenced French neurologist
Paul Broca wrote about the family of his wife, in which the
occurrence of many cancers, particularly of the breast, strongly
suggested the presence of a genetic predisposition [1]. It
was to be more than a hundred years before the discovery of
the structure of DNA and rapid advances in molecular
technology would allow the first major breast cancer
susceptibility gene, BRCA1, to be mapped to chromosome
17q [2]. In families linked to the BRCA1 locus, a much
younger age at onset than average and the frequent occur-
rence of ovarian cancers were noted to be typical. At about
the same time, the cause of a rare but devastating familial
cancer syndrome was identified; mutations in the TP53 gene
had also been found to account for the very rare Li Fraumeni
syndrome associated with very young onset breast cancers and
childhood malignancy, particularly soft tissue sarcomas [3,4].
A second major breast cancer susceptibility gene, BRCA2,
was mapped to chromosome 13q in 1994 shortly before the
sequence of the BRCA1 gene was clarified and family-
specific disease-causing mutations started to be reported
[5,6]. The full BRCA2 gene sequence was reported in 1995
[7]. Families with mutations in the BRCA2 gene were noted
to be more likely to contain a male breast cancer case than
might be expected by chance (and more than had been seen
in families due to BRCA1 mutations); ovarian and fallopian
tube cancers still occurred with increased frequency but
overall not as frequently as in BRCA1-associated families.
With the discovery of the correct gene sequences for
BRCA1 and BRCA2 it became possible to offer predictive
genetic testing to members of families in which the causative
gene mutation had been identified. Predictive testing for
breast cancer susceptibility was introduced as a clinical
service from the mid-1990s in some centres in the UK [8].
Families in which mutations were identified through research
studies were the first to be informed [9]. Many of these
families had been identified because of their high incidence
of cancer, and so inevitably the estimated lifetime chance that
a carrier of one of these genes would develop cancer was
high [10,11].
The BRCA1 and BRCA2 genes are very large, and mutation
testing was either very expensive (in the USA) or very slow (in
European countries) when it first became available. It soon
became clear that mutations in these genes accounted for a
relatively small proportion of all families with breast cancer
clusters. Families with four or more cancer cases developing
at young age, particularly those families in which ovarian
cancers occurred, were more likely to yield pathogenic muta-
tions when DNA from a cancer-affected family member was
screened for mutations. Smaller clusters of later onset cancers,
although clearly familial, were noted to have a much lower
probability of harbouring a BRCA1 or BRCA2 mutation [12].
In the presence of a BRCA1 or BRCA2 mutation, the lifetime
risk for developing breast cancer may be as high as 80% to
90%, although other genes and lifestyle factors may reduce
the lifetime risk to levels as low as 26%. Ovarian cancer risk
in BRCA1 gene carriers is estimated at about 50%, but again
this risk is likely to be modified by both genetic and other risk
factors. For BRCA2, ovarian cancer risk is about 15%, but all
these average risks are likely to be modified by context [13].
Other breast cancer susceptibility genes
During the past decade, no other highly penetrant breast
cancer susceptibility genes like BRCA1 and  BRCA2 have
emerged, despite huge efforts using linkage-based studies in
large breast cancer familial clusters. A variety of candidate
genes were investigated and evidence presented of their
involvement in breast cancer susceptibility but with much
lower associated risks than for BRCA1 and BRCA2 [14-17].
It was realized that it was likely that there were no more high
penetrance genes to be discovered, and that much of the
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remaining familial risk would be due to common variants in
multiple genes, each conferring only very small increases in
lifetime breast cancer risk [18]. As techniques for genotyping
common variants (polymorphisms) across the entire genome
became more economically viable, large cohorts of breast
cancer patients (cases) and unaffected individuals (controls)
were evaluated in genome-wide association studies [19].
Recently, these led to the discovery of several genetic variants,
common in the general population, that confer an increase in
lifetime breast cancer risk with odds ratios (compared with the
population average) of the order of 1.3 [20-22].
Risk assessment using these genetic variants with much
lower penetrance presents an interesting challenge for the
future. Incorporating the seven main risk alleles of the low
penetrance type discovered through genome-wide associa-
tion studies, it is clear that not only would it be a very rare
occurrence to carry all seven high risk alleles, but also the
lifetime risks conferred are modest at best even in the
presence of all seven alleles [23]. Incorporation of the effect
of these common variants into risk prediction algorithms that
take other known epidemiological risk factors into account
does not result in a major improvement in risk prediction (at
least hypothetically) [24]. The nature of the case-control
cohorts thus far studied inevitably leads to findings that are
more likely to apply to oestrogen receptor positive breast
cancers, because these are the more frequent type of breast
cancer overall. This may mean that a group identified as being
at risk on the basis of today’s single nucleotide polymor-
phisms could benefit more from intervention with a chemo-
preventive option such as tamoxifen [25]. However, variants
that alter the rate of metabolism of tamoxifen could prevent
any benefit in a proportion of the population [26].
Where risks conferred by a single gene mutation (pene-
trance) is high and inheritance is clear (usually autosomal
dominant), the use of genetic testing in risk prediction and
risk management are relatively straightforward. This is the
case for BRCA1 and BRCA2 gene mutations, although risks
are still clearly affected by low penetrance genetic variants as
well as lifestyle factors [27-29].
In conclusion, testing of multiple single nucleotide poly-
morphisms to predict lifetime risk of breast cancer is not
clinically valuable for an individual at present. However, over
the coming decade, as most breast cancer risk associated
genetic variants are identified and a clearer picture of gene-
gene and gene-environment interactions emerges, it is likely
that genetic profiles may help to guide selection of women for
earlier mammographic screening and for targeted risk-
reducing strategies, potentially including chemoprevention or
lifestyle changes (for example, weight control, earlier child-
bearing and longer breast feeding). Whether enough women
will be prepared to change their lifestyle radically and from a
young age in order to ameliorate predicted breast cancer risk
remains to be seen.
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